Immunogenicity and pharmacokinetics of guselkumab among patients with moderate‐to‐severe psoriasis in VOYAGE‐1 and VOYAGE‐2
Open Access
- 28 July 2023
- journal article
- letter
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (12) , E1375-E1379
Abstract
No abstract availableFunding Information
- Janssen Research and Development
This publication has 8 references indexed in Scilit:
- Anti‐drug antibodies of IL‐23 inhibitors for psoriasis: a systematic reviewJournal of the European Academy of Dermatology and Venereology, 2022
- Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approachJournal of the European Academy of Dermatology and Venereology, 2020
- Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumabBritish Journal of Dermatology, 2019
- Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque PsoriasisJournal of Investigative Dermatology, 2018
- Impact of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis: results of the PREDIR studyJournal of Dermatological Treatment, 2017
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trialJournal of the American Academy of Dermatology, 2017
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trialJournal of the American Academy of Dermatology, 2017
- Immunogenicity of engineered antibodiesMethods, 2005